Integra LifeSciences' SurgiMend PRS Meshed Boosts ADM Line
Zacks Investment Research | Oct 03, 2017 09:15PM ET
Following the CE Mark approval earlier this month, Integra LifeSciences Holdings Corporation (NASDAQ:IART) recently announced the launch of meshed acellular dermal tissue matrix (ADM) — SurgiMend PRS Meshed — for both pre- and sub-pectoral breast reconstruction in Europe.
The SurgiMend PRS Meshed solution allows patients to opt for just one single-stage implant breast reconstruction post-mastectomy, instead of multiple-stage surgery. This launch is expected to widen the company’s portfolio of acellular dermal tissue matrix for plastic and reconstructive surgery, including breast reconstruction.
Along with this announcement, the global medical technology company announced that this collagen matrix SurgiMend PRS Meshed featuring a 2: 1 meshing pattern, will be available in a 20 centimeters (cms) X 10 cms configuration that expands to roughly 18 cms X 22 cms when hydrated and fully expanded.
Interestingly, the ADM product line falls under the company’s Orthopedics and Tissue Technologies segment which contributed 43.3% of the company’s total revenues in the last reported quarter. The latest launch is expected to further boost the top-line contribution from this segment.
In May, the company launched SurgiMend MP — a collagen matrix for complex abdominal hernia repair — featuring a highly macroporous design that enables fluid drainage. Also, the company announced the European launch of Dermal Regeneration Template Single Layer "Thin" for dermal repair defects reconstruction in "one-step" procedure in the same month.
Integra LifeSciences’ efforts to grow in the plastic and reconstructive surgery market seem to be strategic as per Technavio data published in Business Wire. Per the report, the global plastic surgery products market is expected to reach a value of around $15 billion, at a CAGR of 9% between 2016 and 2020.
Growing consciousness about appearance among women, increasing awareness and rising expenditure in healthcare and technological advancements are likely to drive demand for cosmetic surgeries over time. This fact is further substantiated by data provided by Global Market Insights, which projects that the global breast implants market is set to reach a worth of roughly $ 1,482.1 million at a CAGR of 4.1% in the 2016-2024 period.
We believe the latest launch will help Integra LifeSciences cash in on the bountiful opportunities in this niche market.
Share Price Performance
In the last six months, Integra LifeSciences has been consistently trading above the broader industry . To date, the stock has gained 21.9%, higher than the 13.5% gain of the broader industry.
Get The News You Want
Zacks Rank & Other Key Picks
Integra LifeSciences currently carries a Zacks Rank #2 (Buy). Other top-ranked stocks in the medical sector are Orthofix International N.V. (NASDAQ:OFIX) , Luminex Corporation (NASDAQ:LMNX) and IDEXX Laboratories, Inc. (NASDAQ:IDXX) . Orthofix International and Luminex Corporation sport a Zacks Rank #1 (Strong Buy), while IDEXX Laboratories carries a Zacks Rank #2. You can see Original post
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.